Table 2 Baseline characteristics of the population for the ERCP episodes
From: Reduced risk of post ERCP pancreatitis in statin users
Variable | Statin group | Non-statin group | P value |
|---|---|---|---|
Age | 67.21 (SD: 12.67) | 55.81 (SD: 17.99) | < 0.05 |
Male gender | 179 (49.31%) | 387 (48.44%) | 0.83 |
PD stent placement | 62 (17.08%) | 115 (14.39%) | 0.27 |
Rectal Indomethacin use | 40 (11.02%) | 103 (12.89%) | 0.42 |
History of post ERCP pancreatitis | 19 (5.23%) | 53 (6.63%) | 0.43 |
PD cannulation | 87 (23.97%) | 184 (23.03%) | 0.78 |
Inpatient procedures | 204 (56.20%) | 411 (51.44%) | 0.55 |
Native papilla | 240 (66.12%) | 550 (68.84%) | 0.36 |